Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) gapped up before the market opened on Tuesday . The stock had previously closed at $2.45, but opened at $3.99. Adaptimmune Therapeutics shares last traded at $4.04, with a volume of 22,121,049 shares changing hands.

ADAP has been the subject of a number of research analyst reports. Zacks Investment Research lowered Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 8th. ValuEngine raised Adaptimmune Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, December 3rd. Finally, Cowen reaffirmed a “buy” rating on shares of Adaptimmune Therapeutics in a research report on Thursday, November 7th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $5.23.

The stock has a market capitalization of $139.24 million, a P/E ratio of -4.21 and a beta of 1.83. The company has a current ratio of 3.93, a quick ratio of 3.93 and a debt-to-equity ratio of 0.15. The company has a 50-day moving average price of $1.34 and a 200 day moving average price of $1.74.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.36) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.03). The firm had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $7.00 million. As a group, research analysts expect that Adaptimmune Therapeutics PLC – will post -1.37 earnings per share for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ADAP. Rock Springs Capital Management LP raised its position in shares of Adaptimmune Therapeutics by 9.4% in the 2nd quarter. Rock Springs Capital Management LP now owns 875,000 shares of the biotechnology company’s stock worth $3,518,000 after acquiring an additional 75,000 shares in the last quarter. Man Group plc raised its position in shares of Adaptimmune Therapeutics by 37.4% in the 2nd quarter. Man Group plc now owns 1,839,225 shares of the biotechnology company’s stock worth $7,394,000 after acquiring an additional 500,595 shares in the last quarter. Bamco Inc. NY raised its position in shares of Adaptimmune Therapeutics by 6.1% in the 2nd quarter. Bamco Inc. NY now owns 172,669 shares of the biotechnology company’s stock worth $694,000 after acquiring an additional 10,000 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Adaptimmune Therapeutics by 21,372.0% in the 3rd quarter. Tower Research Capital LLC TRC now owns 21,472 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 21,372 shares in the last quarter. Finally, Millennium Management LLC raised its position in shares of Adaptimmune Therapeutics by 5.2% in the 3rd quarter. Millennium Management LLC now owns 914,416 shares of the biotechnology company’s stock worth $1,380,000 after acquiring an additional 45,249 shares in the last quarter. 65.06% of the stock is owned by hedge funds and other institutional investors.

Adaptimmune Therapeutics Company Profile (NASDAQ:ADAP)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.

Featured Article: Most Active Stocks

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.